Tamtam Try Tamtam free
Revvity logo

Revvity account plan

Health science solutions revolutionizing healthcare

At a glance

Revvity is a Waltham-based health science company selling life sciences research tools, software and diagnostics, with FY2025 revenue of $2,856.1 million.

Revvity provides instruments, reagents, software and services for life sciences research, drug discovery and diagnostics, to pharmaceutical and biotech companies, laboratories, academic institutions, public health authorities and healthcare organizations in more than 160 countries. It is headquartered in Waltham, Massachusetts, listed on the NYSE as RVTY and part of the S&P 500. FY2025 revenue was $2,856.1 million (up 4%) and net income $241.2 million, with approximately 11,000 employees, roughly 80% of them outside the United States. Prahlad Singh is President and CEO.

Business units

Strategic priorities

Serving AI-driven lab demand
Revvity sees AI companies and pharma needing more wet-lab data; high-content screening orders outran near-term production capacity, and it is building additional capacity for 2027.
Signals software launches
2026 is described as the most significant year of new product launches in Signals' history, including LabGistics, Synthetica, Signals AI and an Anthropic Connector, with ARR growth of 20% plus.
Portfolio focus
Revvity agreed on July 31, 2026 to sell its China Immunodiagnostics business and is adding ACD/Labs and Human Cell Design to Life Sciences.
Footprint and cost efficiency
Severance actions affected approximately 7% of the workforce in 2026 year to date, and R&D and manufacturing were consolidated at the Hopkinton, Massachusetts campus, with efficiency work in Lübeck and Hamburg.
Diagnostics menu expansion
Revvity launched the GSP T1D 3-Plex kit in Europe, its first step into early childhood screening, and is developing a broader T1D assay with Sanofi.
AI and operational excellence
The 10-K strategy includes advancing the use of AI in offerings and internal efficiency, operational excellence and disciplined capital allocation.

Latest results

In Q3 fiscal 2026 (quarter ended October 4, 2026) revenue rose 4% to $728.9 million, with Life Sciences up 11% to $379.6 million and Diagnostics down 2% to $349.3 million. Gross margin rose 380 bps to 57.4% and net income reached $62.3 million ($0.56 per diluted share). On a pro forma basis excluding China Immunodiagnostics, organic growth was 7% and adjusted operating margin 29.4%. For FY2026 management guides to pro forma organic growth of about 5%, an adjusted operating margin of 28.8% and adjusted EPS of $5.40-$5.45.

Investments and deals

ACD/Labs acquisition
Acquired in Q1 2026 for $72.0 million at closing plus up to $8.0 million contingent through 2028; a Toronto scientific software firm with about 200 employees.
Human Cell Design acquisition
Agreement signed in Q3 2026 for €45.0 million plus up to €8.0 million contingent, for a Toulouse biotech making human cell models for metabolic disease research.
China Immunodiagnostics divestiture
A definitive agreement was signed July 31, 2026, with closing expected by the end of FY2027 subject to Chinese approvals.
Capex for digital and production
Capex was $73.5 million in FY2025, and Revvity projects higher FY2026 capex for digital capabilities, product innovations and realigning its production infrastructure.
Share buybacks and debt repayment
It repurchased $820.8 million of shares in FY2025 and repaid the €500.0 million 1.875% notes in Q3 2026; $792.7 million remains under the $1.0 billion program.

Challenges and risks

Research funding uncertainty
U.S. funding and regulatory changes have created a more cautious spending environment for customers.
China diagnostics pressure
China testing policy changes hurt Diagnostics mix, China revenue fell to $425.1 million in FY2025, and APAC declined in Q3 2026.
Tariffs and FX
Tariffs added about $25 million to FY2025 cost of revenue, and approximately 60% of the business is conducted outside the U.S. in foreign currencies.
Single-source suppliers and capacity
Many critical raw materials have only one qualified source, and high-content screening orders outran near-term production capacity.
Goodwill risk
Life Sciences Solutions carries $4.5 billion of goodwill, with only a limited fair-value cushion at the November 2025 test.

What leadership says

“As customers look to build larger biological datasets to train and refine their AI models, they are going to need exponentially more data from the wet lab.”

Prahlad Singh, President and CEO · Q3 2026 earnings call, November 3, 2026

“I believe our third quarter performance fully demonstrated, for the first time since the start of our recent transformation, what our true potential is as a company.”

Prahlad Singh, President and CEO · Q3 2026 earnings call, November 3, 2026

“AI may accelerate hypothesis generation, but those hypotheses still need to be tested, validated and advanced through real-world biological data generation”

Prahlad Singh, President and CEO · Q2 2026 earnings call, August 4, 2026

“are continuing to move back to more normalized spending behavior”

Maxwell Krakowiak, SVP and CFO · On pharma/biotech customers, Q3 2026 earnings call, November 3, 2026

Where a supplier can help

Manufacturing capacity for screening instruments
High-content screening orders outran production capacity and capacity is being added for 2027, an opening for manufacturing equipment, automation and contract manufacturing suppliers.
Supply chain resilience
Single-source raw materials and tariff exposure favour suppliers that can qualify as second sources or cut landed cost.
Software and AI partnerships
The Signals launch wave and work with LLM providers create needs for cloud, AI and data integration partners.
Integration of acquisitions and footprint moves
Integrating ACD/Labs and Human Cell Design, the China divestiture and site consolidation at Hopkinton call for integration, IT separation and facilities support.
Cost efficiency programmes
Restructuring costs of $74.5 million over nine months of 2026 and continued efficiency work point to procurement, automation and shared-services offers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Revvity?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Revvity

What does Revvity do?

Revvity sells instruments, reagents, software and services for life sciences research and drug discovery, and diagnostics such as immunodiagnostics and newborn screening.

What is Revvity's revenue?

FY2025 revenue was $2,856.1 million, up 4%; Q3 2026 revenue was $728.9 million.

How many employees does Revvity have?

Approximately 11,000 at December 28, 2025, roughly 80% of them outside the United States.

Who leads Revvity?

Prahlad Singh is President and CEO and Maxwell Krakowiak is SVP and CFO.

What is Revvity's strategy?

Grow in high-growth markets through innovation, Signals software and AI-driven lab demand, sharpen the portfolio by selling China Immunodiagnostics, and improve efficiency.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)